^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

Published date:
11/02/2021
Excerpt:
The pharmacokinetics, immunogenicity, CD70 expression, and CD70/CD27 biology were also assessed....The overall response rate was 23%; this included 1 complete response and 5 partial responses (PRs) in 26 of the 27 evaluable patients. In addition, 9 patients achieved stable disease....Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL.
DOI:
10.1002/cncr.34005